Table 1 Comparison of baseline characteristics of patients in training/validation set and test set
Feature | Training and validation set patients N = 4493 | Test set patients N = 499 | p-value |
|---|---|---|---|
G5 CKD progression during study period (%) | 1437 (31.98%) | 139 (27.86%) | 0.067 |
RRT initiation during study period (%) | 882 (19.63%) | 107 (21.44%) | 0.366 |
eGFR on recruitment (ml/min/1.73m2) | 24.43 (24.32—24.56) | 24.58 (24.24—24.93) | 0.451 |
Demographic data | |||
Age (years) (95% CI) | 70.54 (70.17—70.92) | 70.72 (69.62—71.82) | 0.771 |
Female gender (%) | 1971 (43.87%) | 216 (43.29%) | 0.841 |
Medical History | |||
Hypertension | 2585 (57.53%) | 289 (57.92%) | 0.908 |
Type 2 diabetes mellitus | 1479 (32.92%) | 172 (34.47%) | 0.517 |
Heart failure | 1035 (23.04%) | 123 (24.65%) | 0.182 |
Glomerular disorders | 996 (22.17%) | 107 (21.44%) | 0.754 |
Biochemical Data | |||
Creatinine (µmol/L) | 194.47 (192.97—195.98) | 194.88 (190.1—199.66) | 0.869 |
Urea (mmol/L) | 13.07 (12.93—13.21) | 12.97 (12.55—13.38) | 0.628 |
ALT (U/L) | 19.11 (18.64—19.58) | 18.47 (17.39—19.56) | 0.393 |
AST (U/L) | 34.18 (29.32—39.04) | 34.14 (24.27—44.01) | 0.996 |
ALP (U/L) | 87.40 (86.0—88.8) | 88.22 (84.80 -s 91.65) | 0.708 |
Albumin (g/L) | 39.16 (39.02—39.3) | 39.41 (39.01—39.81) | 0.258 |
Urate (mmol/L) | 0.47 (0.46—0.48) | 0.47 (0.46—0.49) | 0.627 |
Calcium (mmol/L) | 2.32 (2.32—2.33) | 2.34 (2.33—2.35) | 0.019 |
Phosphate(mmol/L) | 1.17 (1.17- 1.18) | 1.19 (1.17—1.21) | 0.071 |
Ca X PO4 (mg2/dL2) | 33.75 (33.55—33.94) | 34.56 (33.94—35.18) | 0.011 |
Haemoglobin (g/L) | 11.43 (11.4—11.8) | 11.60 (11.4—11.8) | 0.121 |
Haemoglobin a1c (%) | 7.80 (7.73—7.87) | 7.89 (7.7—8.09) | 0.400 |
Spot urine protein: creatinine (mg/mg Cr) | 2.20 (2.00—2.41) | 1.75 (1.35—2.16) | 0.156 |